Eugene Schiff
Expertise in
9
conditions

Dr. Eugene Schiff

Gastroenterology
Umhc-Sylvester Comprehensive Cancer Center
1475 NW 12th Ave, 
Miami, FL 
59 Years of Experience
Expertise in
9
conditions
Umhc-Sylvester Comprehensive Cancer Center
1475 NW 12th Ave, 
Miami, FL 

Overview

Eugene Schiff is a Gastroenterologist practicing medicine in Miami, Florida. He has been practicing medicine for over 59 years.

Dr. Schiff is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis C, Nonalcoholic Steatohepatitis (NASH), Hepatitis B, and Liver Transplant.

He is actively involved in clinical research, co-authoring 66 peer reviewed articles and participating in 15 clinical trials.

Specialties

Gastroenterology

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

Umhc-Sylvester Comprehensive Cancer Center
1475 NW 12th Ave, Miami, FL 33136
Other Locations
Univ of Miami-Division of Pharmacology
1500 NW 12th Ave, Miami, FL 33136

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Drug
Study Drug: HM15211
Study Phase: Phase 2
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Enrollment Status: Terminated
Publish Date: September 17, 2025
Intervention Type: Other
A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 24, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
Enrollment Status: Completed
Publish Date: February 28, 2024
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Enrollment Status: Completed
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drugs: GSK3228836, Nucleos(t)ide therapy
Study Phase: Phase 2
Rapid Diagnostics for HIV and Hepatitis - Multiplo HBc/HIV/HCV and Reveal HBsAg
Rapid Diagnostics for HIV and Hepatitis - Multiplo HBc/HIV/HCV and Reveal HBsAg
Enrollment Status: Withdrawn
Publish Date: April 21, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
Enrollment Status: Completed
Publish Date: December 06, 2021
Intervention Type: Drug
Study Phase: Phase 4
View 9 Less Clinical Trials

65 Total Publications

Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses.
Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses.
Journal: JHEP reports : innovation in hepatology
Published: August 17, 2023
Similar Doctors
Expertise in
9
conditions
Dr. Maria Abreu
Gastroenterology
Expertise in
9
conditions
Dr. Maria Abreu
Gastroenterology
Referral may be required

Office

1475 NW 12th Ave Fl 1, 
Miami, FL 
 (0.6 miles away)
305-243-8644
Languages Spoken:
English
See accepted insurances

Maria Abreu is a Gastroenterologist practicing medicine in Miami, Florida. Dr. Abreu is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Ulcerative Colitis, Crohn's Disease, Viral Gastroenteritis, Colonoscopy, and Ileostomy.

Expertise in
20
conditions
Dr. Pichamol Jirapinyo
Gastroenterology
Expertise in
20
conditions
Dr. Pichamol Jirapinyo
Gastroenterology
Referral may be required

BariEndo

382 NE 191st St, 
Miami, FL 
 (11.2 miles away)
305-921-4219
Languages Spoken:
English
See accepted insurances

Pichamol Jirapinyo is a Gastroenterologist practicing medicine in Miami, Florida. Dr. Jirapinyo is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Obesity, Gastroesophageal Reflux Disease (GERD), Bile Duct Stricture, Gastric Bypass, and Endoscopy. Dr. Jirapinyo is board certified in AB Internal Medicine (Gastroenterology).

Expertise in
53
conditions
Dr. Andres Gelrud
Gastroenterology
Expertise in
53
conditions
Dr. Andres Gelrud
Gastroenterology
Referral may be required

Office

9408 SW 87th Ave Ste 200, 
Miami, FL 
 (12.6 miles away)
305-913-0666
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andres Gelrud is a Gastroenterologist practicing medicine in Miami, Florida. Dr. Gelrud is highly rated in 53 conditions, according to our data. His clinical expertise encompasses Hereditary Pancreatitis, Chronic Pancreatitis, Acute Pancreatitis, Pancreatectomy, and Endoscopy.

Frequently Asked Questions about Dr. Eugene Schiff

How do I make an appointment with Dr. Eugene Schiff?

You can book an appointment with Dr. Eugene Schiff by calling their office at 305-243-1000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Eugene Schiff a top-rated expert for Hepatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Eugene Schiff is classified as an Elite expert for Hepatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Eugene Schiff specialize in?

While Dr. Eugene Schiff is a Gastroenterology, they have specific expertise in Hepatitis, Hepatitis C, and Nonalcoholic Steatohepatitis (NASH). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Eugene Schiff participate in research or clinical trials?

Yes. Dr. Eugene Schiff has published 65 articles and abstracts on conditions like Hepatitis. You can view a list of Dr. Eugene Schiff's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Eugene Schiff accept my insurance?

Dr. Eugene Schiff accepts most major insurance plans, including Aetna and AvMed. We recommend calling the office directly at 305-243-1000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schiff's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile